Chongqing Pharscin Pharmaceutical Co., Ltd.

XSEC:002907 Stock Report

Market Cap: CN¥6.0b

Chongqing Pharscin Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Chongqing Pharscin Pharmaceutical's earnings have been declining at an average annual rate of -24.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 3.3% per year. Chongqing Pharscin Pharmaceutical's return on equity is 3.8%, and it has net margins of 7.9%.

Key information

-24.1%

Earnings growth rate

-24.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-3.3%
Return on equity3.8%
Net Margin7.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Chongqing Pharscin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:002907 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247916331068
30 Jun 247493929375
31 Mar 247324328277
31 Dec 236923326278
30 Sep 237397028369
30 Jun 237788830167
31 Mar 237709929464
01 Jan 237859829659
30 Sep 227627529355
30 Jun 227788728746
31 Mar 228198529744
01 Jan 228469229742
30 Sep 2190311428439
30 Jun 2193911328240
31 Mar 2194212827338
31 Dec 2088211926836
30 Sep 2084012728233
30 Jun 2081614029730
31 Mar 2082116631524
31 Dec 1984217033426
30 Sep 1979616333122
30 Jun 1975616732718
31 Mar 1973013932320
31 Dec 1870313731615
30 Sep 1868613130913
30 Jun 1866112829315
31 Mar 1863112028810
31 Dec 175921122709
30 Sep 176021122684
31 Dec 16552962490
31 Dec 15469742050
31 Dec 14426592030

Quality Earnings: 002907 has a large one-off gain of CN¥24.0M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 002907's current net profit margins (7.9%) are lower than last year (9.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002907's earnings have declined by 24.1% per year over the past 5 years.

Accelerating Growth: 002907's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002907 had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 002907's Return on Equity (3.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies